ZNF667 and central nervous system cancer: Here, the expressing condition of ZNF667-AS1 in 155 glioma patients was first examined, confirming that the ZNF667-AS1 expression was distinctly upregulated in glioma specimens in comparison with matched nontumor brain tissues, which was inconsistent with its expression trend in other several tumors.